Welcome to the WSC 2021 Interactive Program

The congress will officially run on Central European Summer Time (CEST/GMT+2)

To convert the congress times to your local time Click Here

The viewing of sessions cannot be accessed from this conference calendar.
All sessions are accessible via the Main Lobby on the Virtual Platform.

- WSC TV   - Live Session   - Pre-Recorded Session with Live Q&A  - On Demand Session (watch anytime)  - Session with Voting

Displaying One Session

Session Type
Case discussion
Date
28.10.2021, Thursday
Session Time
15:45 - 17:15
Room
CASE DISCUSSIONS
Session Icon
Live Session

Moya-Moya Syndrome: What’s new?

Session Type
Case discussion
Date
28.10.2021, Thursday
Session Time
15:45 - 17:15
Room
CASE DISCUSSIONS
Lecture Time
15:45 - 15:59

Abstract

Abstract Body

Moyamoya disease (MMD) is an uncommon vascular disease of unknown etiology to cause bilateral progressive stenosis and occlusion of arteries of the circle of Willis, and preferentially affects children and young adults, which is seen across the world, but is more common in East Asia. The word “moyamoya” means “puff of smoke” in Japanese, a term describing the appearance of net-like tiny collateral blood vessels. MMD may cause TIA, stroke, aneurysm, or bleeding in the brain. Ischemic stroke is dominant in children and hemorrhagic stroke is dominant in adults. Moyamoya-like vasculopathy develops in association with various systemic diseases and conditions, which is termed moyamoya syndrome or quasi-MMD. Unilateral MMD without any underlying disease is diagnosed with probable MMD. Ring finger protein (RNF213) was identified as a susceptibility gene for Asian populations. Experimental studies have suggested that RNF213 is related to angiogenesis and vascular inflammation. Recent studies reported that RNF213 variant increases the risk of atherothrombotic stroke and intracranial arterial stenosis. There is no medical treatment or endovascular intervention proven to halt the progression of MMD or prevention of stroke. In the Japan Adult Moyamoya (JAM) trial, which compared bilateral extracranial-intracranial direct bypass and conservative care in 80 patients with MMD with an age range of 18–65 years, patients in the bypass surgery group at the primary endpoint experienced significantly less recurrent intracranial hemorrhage, completed stroke, or crescendo TIA.

Hide

Infection and Stroke

Session Type
Case discussion
Date
28.10.2021, Thursday
Session Time
15:45 - 17:15
Room
CASE DISCUSSIONS
Lecture Time
15:59 - 16:13

Genetic Causes of Stroke

Session Type
Case discussion
Date
28.10.2021, Thursday
Session Time
15:45 - 17:15
Room
CASE DISCUSSIONS
Lecture Time
16:13 - 16:27

Cerebral Sinus Thrombosis

Session Type
Case discussion
Date
28.10.2021, Thursday
Session Time
15:45 - 17:15
Room
CASE DISCUSSIONS
Lecture Time
16:27 - 16:41

CNS Vasculopathy

Session Type
Case discussion
Date
28.10.2021, Thursday
Session Time
15:45 - 17:15
Room
CASE DISCUSSIONS
Lecture Time
16:41 - 16:55

Live Q&A

Session Type
Case discussion
Date
28.10.2021, Thursday
Session Time
15:45 - 17:15
Room
CASE DISCUSSIONS
Lecture Time
16:55 - 17:15